Detalhe da pesquisa
1.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
J Neurol Neurosurg Psychiatry
; 94(9): 757-768, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37221052
2.
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Mult Scler
; 29(8): 945-955, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37282545
3.
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Ann Neurol
; 89(5): 895-910, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33724534
4.
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Mult Scler
; 28(6): 925-932, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34595983
5.
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Br J Clin Pharmacol
; 88(8): 3803-3812, 2022 08.
Artigo
Inglês
| MEDLINE | ID: mdl-35332558
6.
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Mult Scler
; 27(13): 2052-2061, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33538237
7.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Lancet
; 394(10206): 1352-1363, 2019 10 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31495497
8.
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
J Am Acad Dermatol
; 80(4): 1013-1021, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30550828
9.
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med
; 197(1): 94-103, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28787186
10.
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
Br J Clin Pharmacol
; 80(6): 1337-49, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26182954
11.
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Lancet Neurol
; 23(6): 588-602, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38760098
12.
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
Eur Respir J
; 41(2): 330-8, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22743678
13.
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
Rheumatol Ther
; 10(6): 1795-1808, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37792260
14.
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Ann Clin Transl Neurol
; 10(12): 2413-2420, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37804003
15.
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.
Am J Respir Crit Care Med
; 194(1): 118-20, 2016 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27367889
16.
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Mult Scler Relat Disord
; 57: 103352, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35158461
17.
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design.
Eur Heart J Cardiovasc Pharmacother
; 8(3): 243-252, 2022 05 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33493256
18.
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Mult Scler Relat Disord
; 57: 103356, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-35158465
19.
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
EBioMedicine
; 86: 104321, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36370634
20.
Trend tests for genetic association using population-based cross-sectional complex survey data.
Biostatistics
; 11(1): 48-56, 2010 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19745160